Reneo Pharmaceuticals
RPHM

$1.50

0%

Market Cap: $50.1M

About: Reneo Pharmaceuticals Inc is a clinical-stage pharmaceutical company. It is focused on the development of therapies for patients with rare genetic mitochondrial diseases, which are often associated with the inability of mitochondria to produce adenosine triphosphate (ATP). The company is developing REN001 to modulate genes critical to metabolism and generation of ATP, which is the primary source of energy for cellular processes.

Employees: 8

Healthcare Pharmaceutical Preparations

0

Funds holding %

of 6,710 funds

–

Analysts bullish %

Fund manager confidence

Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)

18% more first-time investments, than exits

New positions opened: 20 | Existing positions closed: 17

5% more funds holding

Funds holding: 62 [Q1] → 65 (+3) [Q2]

0.43% more ownership

Funds ownership: 82.83% [Q1] → 83.26% (+0.43%) [Q2]

0% more funds holding in top 10

Funds holding in top 10: 2 [Q1] → 2 (+0) [Q2]

8% less capital invested

Capital invested by funds: $45.8M [Q1] → $42.2M (-$3.63M) [Q2]

33% less repeat investments, than reductions

Existing positions increased: 14 | Existing positions reduced: 21

See Fund Rankings

Research analyst outlook

We haven’t received any recent analyst ratings for RPHM.

See Analyst Rankings

Financial journalist opinion

RPHM Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Reneo Pharmaceuticals, Inc. Is Fair to Shareholders

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the merger of Reneo Pharmaceuticals, Inc. (NASDAQ: RPHM) and OnKure, Inc. is fair to Reneo shareholders. Pre-merger Reneo shareholders are expected to own approximately 31% of the combined company. Halper Sadeh encourages Reneo shareholders to click here to learn more about their legal rights and options or contact Daniel Sadeh or Zachary Halper at (212) 763-0060 or sadeh@halpersadeh.com or zhalpe.

RPHM Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Reneo Pharmaceuticals, Inc. Is Fair to Shareholders

Reneo Pharmaceuticals Reports Second Quarter 2024 Financial Results

IRVINE, Calif., Aug. 13, 2024 (GLOBE NEWSWIRE) -- Reneo Pharmaceuticals, Inc. (Nasdaq: RPHM), a pharmaceutical company historically focused on the development and commercialization of therapies for patients with rare genetic mitochondrial diseases, today reported financial results for the second quarter ended June 30, 2024.

Reneo Pharmaceuticals Reports Second Quarter 2024 Financial Results

STOCKHOLDER INVESTIGATION: The M&A Class Action Firm Investigates Merger of Reneo Pharmaceuticals, Inc. - RPHM

NEW YORK, June 26, 2024 (GLOBE NEWSWIRE) -- Monteverde & Associates PC (the “M&A Class Action Firm”), has recovered money for shareholders and is recognized as a Top 50 Firm in the 2018-2022 ISS Securities Class Action Services Report. We are headquartered at the Empire State Building in New York City and is investigating Reneo Pharmaceuticals, Inc. (Nasdaq: RPHM ), relating to its proposed merger with OnKure, Inc. Under the terms of the agreement, Reneo stockholders are expected to own approximately 31% of the combined company.

STOCKHOLDER INVESTIGATION: The M&A Class Action Firm Investigates Merger of Reneo Pharmaceuticals, Inc. - RPHM

STOCKHOLDER INVESTIGATION: The M&A Class Action Firm Investigates Merger of Reneo Pharmaceuticals, Inc. - RPHM

NEW YORK , June 24, 2024 /PRNewswire/ -- Monteverde & Associates PC (the "M&A Class Action Firm"), has recovered money for shareholders and is recognized as a Top 50 Firm in the 2018-2022 ISS Securities Class Action Services Report. We are headquartered at the Empire State Building in New York City and is investigating Reneo Pharmaceuticals, Inc. (Nasdaq: RPHM), relating to its proposed merger with OnKure, Inc. Under the terms of the agreement, Reneo stockholders are expected to own approximately 31% of the combined company.

STOCKHOLDER INVESTIGATION: The M&A Class Action Firm Investigates Merger of Reneo Pharmaceuticals, Inc. - RPHM

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates AAN, RPHM on Behalf of Shareholders

NEW YORK, June 21, 2024 (GLOBE NEWSWIRE) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to:

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates AAN, RPHM on Behalf of Shareholders

STOCKHOLDER INVESTIGATION: The M&A Class Action Firm Investigates Merger of Reneo Pharmaceuticals, Inc. - RPHM

NEW YORK, June 21, 2024 (GLOBE NEWSWIRE) -- Monteverde & Associates PC (the “M&A Class Action Firm”), has recovered money for shareholders and is recognized as a Top 50 Firm in the 2018-2022 ISS Securities Class Action Services Report. We are headquartered at the Empire State Building in New York City and is investigating Reneo Pharmaceuticals, Inc. (Nasdaq: RPHM ), relating to its proposed merger with OnKure, Inc. Under the terms of the agreement, Reneo stockholders are expected to own approximately 31% of the combined company.

STOCKHOLDER INVESTIGATION: The M&A Class Action Firm Investigates Merger of Reneo Pharmaceuticals, Inc. - RPHM

RENEO PHARMACEUTICALS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Reneo Pharmaceuticals, Inc. - RPHM

NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed merger of Reneo Pharmaceuticals, Inc. (NasdaqGM: RPHM) (the “Company”) and OnKure, Inc. Upon completion of the proposed transaction, pre-merger Reneo shareholders are expected to own approximately 31% of the combined company. KSF is seeking to determine whether the merger and the process that led to it are adequate, o.

RENEO PHARMACEUTICALS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Reneo Pharmaceuticals, Inc. - RPHM

STOCKHOLDER INVESTIGATION: The M&A Class Action Firm Announces An Investigation of Reneo Pharmaceuticals, Inc. - RPHM

NEW YORK , May 13, 2024 /PRNewswire/ -- Monteverde & Associates PC (the "M&A Class Action Firm"), has recovered money for shareholders and is recognized as a Top 50 Firm in the 2018-2022 ISS Securities Class Action Services Report. We are headquartered at the Empire State Building in New York City and is investigating Reneo Pharmaceuticals, Inc. (Nasdaq: RPHM), relating to its proposed merger with OnKure, Inc. Under the terms of the agreement, Reneo stockholders are expected to own approximately 31% of the combined company.

STOCKHOLDER INVESTIGATION: The M&A Class Action Firm Announces An Investigation of Reneo Pharmaceuticals, Inc. - RPHM

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates SQSP, RPHM

NEW YORK , May 13, 2024 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Squarespace, Inc. (NYSE: SQSP)'s sale to Permira for $44.00 per share in cash. If you are a Squarespace shareholder, click here to learn more about your rights and options.

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates SQSP, RPHM

Shareholder Alert: Ademi LLP investigates whether Reneo Pharmaceuticals, Inc. has obtained a Fair Price in its Transaction with OnKure

MILWAUKEE , May 13, 2024 /PRNewswire/ -- Ademi LLP is investigating Reneo (Nasdaq: RPHM) for possible breaches of fiduciary duty and other violations of law in its going private transaction with OnKure. Click here to learn how to join the https://www.ademilaw.com/case/reneo-pharmaceuticals-inc or call Guri Ademi toll-free at 866-264-3995.

Shareholder Alert: Ademi LLP investigates whether Reneo Pharmaceuticals, Inc. has obtained a Fair Price in its Transaction with OnKure

See News Rankings